Publications

1. Advice - reimburse dostarlimab (Jemperli®) for the treatment of endometrial cancer

   The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse dostarlimab ...

   Report | 10-07-2024

2. Advice - reimburse sacituzumab govitecan (Trodelvy®) for the treatment of breast cancer (re-evaluation)

   The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse sacituzumab govitecan ...

   Report | 09-07-2024

3. Advice - reimburse naldemedine (Rizmoic®) for the treatment of constipation due to the use of strong analgesics (opioids)

   The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse naldemedine (Rizmoic ...

   Report | 01-07-2024

4. Advice - extending the reimbursement of axicabtagene ciloleucel (Yescarta®) for the treatment of lymphoma

   The National Health Care Institute has advised the Minister for Medical Care to extend the reimbursement of axicabtagene ...

   Report | 26-06-2024

5. Advice - do not reimburse loncastuximab tesirine (Zynlonta®) for the treatment of lymphoma

   The National Health Care Institute has advised the Minister for Medical Care to not reimburse loncastuximab tesirine (Zynlonta®) ...

   Report | 12-06-2024

6. Advice - do not reimburse glofitamab (Columvi®) for the treatment of lymphoma

   The National Health Care Institute has advised the Minister for Medical Care to not reimburse glofitamab (Columvi®) from the ...

   Report | 12-06-2024

7. Advice - reimburse pegunigalsidase alfa (Elfabrio®) for the treatment of Fabry disease

   The National Health Care Institute has advised the Minister for Medical Care to reimburse pegunigalsidase alfa (Elfabrio®) from ...

   Report | 12-06-2024

8. Advice - reimburse midazolam nasal spray (Nasolam®) for the treatment of epilepsy

   The National Health Care Institute has advised the Minister for Medical Care to reimburse midazolam nasal spray (Nazolam®) from ...

   Report | 07-06-2024

9. Advice - reimburse avalglucosidase alfa (Nexviadyme®) for the treatment of Pompe disease

   The National Health Care Institute has advised the Minister for Medical Care to reimburse avalglucosidase alfa (Nexviadyme®), ...

   Report | 30-05-2024

10. Advice - reimburse efgartigimod alfa (Vyvgart®) for the treatment of myasthenia gravis

    The National Health Care Institute has advised the Minister for Medical Care to reimburse efgartigimod alfa (Vyvgart®) from the ...

    Report | 29-05-2024